[HTML][HTML] Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities
SP Hack, AX Zhu, Y Wang - Frontiers in Immunology, 2020 - frontiersin.org
Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
[HTML][HTML] Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma
R Xing, J Gao, Q Cui, Q Wang - Frontiers in immunology, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually
diagnosed in advanced stages due to late symptom manifestation with very limited …
diagnosed in advanced stages due to late symptom manifestation with very limited …
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline
JD Gordan, EB Kennedy, GK Abou-Alfa… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
TF Greten, GK Abou-Alfa, AL Cheng… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options
and faced extremely poor prognoses if their disease progressed after standard-of-care …
and faced extremely poor prognoses if their disease progressed after standard-of-care …
[HTML][HTML] The current landscape of clinical trials for systemic treatment of HCC
F Foerster, PR Galle - Cancers, 2021 - mdpi.com
Simple Summary Liver cancer is a life-threatening disease. Apart from surgery and catheter-
guided therapies, drugs are a central pillar for its treatment. Clinical trials are research …
guided therapies, drugs are a central pillar for its treatment. Clinical trials are research …
[HTML][HTML] Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
O Michielin, AK Lalani, C Robert… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …
Systemic therapy of advanced hepatocellular carcinoma
For a decade, sorafenib remained the only approved first-line treatment and standard of care
for advanced hepatocellular carcinoma. The treatment landscape has been evolving rapidly …
for advanced hepatocellular carcinoma. The treatment landscape has been evolving rapidly …
Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma
L Bassaganyas, R Pinyol, R Esteban-Fabró… - Clinical Cancer …, 2020 - AACR
Purpose: Chromosomal instability is a hallmark of cancer that results in broad and focal copy-
number alterations (CNAs), two events associated with distinct molecular, immunologic, and …
number alterations (CNAs), two events associated with distinct molecular, immunologic, and …
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
E Lai, G Astara, P Ziranu, A Pretta, M Migliari… - Critical Reviews in …, 2021 - Elsevier
Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy
has been explored in this disease in order to improve survival outcomes. Nowadays …
has been explored in this disease in order to improve survival outcomes. Nowadays …
[HTML][HTML] Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma
R Mohr, F Jost-Brinkmann, B Özdirik… - Frontiers in …, 2021 - frontiersin.org
The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …
different malignancies has largely changed our understanding of cancer treatment. After …